File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: S-1 Versus S-1 Plus Cisplatin as First-line Treatment for Metastatic Gastric Cancer

TitleS-1 Versus S-1 Plus Cisplatin as First-line Treatment for Metastatic Gastric Cancer
Authors
Issue Date2017
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.org
Citation
Hong Kong Journal of Radiology, 2017, v. 20, p. 318-322 How to Cite?
AbstractObjective: To compare S-1 with S-1 plus cisplatin (SP) as first-line treatment for metastatic gastric cancer. Methods: Records of patients with metastatic gastric cancer who received either the S-1 or SP regimen as first-line treatment for metastatic gastric cancer between January 2013 and December 2014 in Queen Mary Hospital were retrospectively reviewed. Baseline characteristics, overall response rate, median progression-free survival (PFS), overall survival (OS), and toxicity of the two groups were compared. Results: During the study period, 17 patients received S-1 and 13 patients received SP. The median patient ages were 69 and 57 years, respectively. In the S-1 group, more patients were aged ≥70 years (47.1% vs. 7.7%, p = 0.02), fewer patients underwent surgical resection of primary tumours (23.5% vs. 53.8%, p = 0.09), more patients required initial dose reduction (70.6% vs. 15.4%, p = 0.001), and fewer patients received subsequent chemotherapy (5.9% vs. 30.8%, p = 0.07) compared with the SP group. The S-1 group had a lower response rate (11.8% vs. 46.2%, p = 0.049). Nonetheless, S-1 and SP groups were comparable for clinical benefit rate (47.1% vs. 77.0%, p = 0.14), median PFS (34.5 weeks vs. 28.8 weeks, p = 0.72), median OS (46.4 weeks vs. 52.7 weeks, p = 0.18), and 30-day mortality (11.8% vs. 7.7%, p = 1.00). There was a trend of improved OS in the SP group (hazard ratio = 1.84, 95% confidence interval = 0.74-4.55, p = 0.185). The two groups were also comparable for the rate of grade 3/4 neutropaenia (17.7% vs. 38.5%, p = 0.24) and grade 3/4 diarrhoea (5.9% vs. 30.8%, p = 0.14). There was no treatment-related death. Conclusion: Both S-1 and SP regimens are effective and safe as first-line treatment for metastatic gastric cancer. A dose-adjusted S-1 regimen is a viable option for patients with advanced age and marginal performance status.
Persistent Identifierhttp://hdl.handle.net/10722/258364
ISSN
2015 SCImago Journal Rankings: 0.113

 

DC FieldValueLanguage
dc.contributor.authorLau, KS-
dc.contributor.authorLam, KO-
dc.contributor.authorChan, WLW-
dc.contributor.authorLee, VHF-
dc.contributor.authorKwong, DLW-
dc.contributor.authorLeung, TW-
dc.date.accessioned2018-08-22T01:37:18Z-
dc.date.available2018-08-22T01:37:18Z-
dc.date.issued2017-
dc.identifier.citationHong Kong Journal of Radiology, 2017, v. 20, p. 318-322-
dc.identifier.issn2223-6619-
dc.identifier.urihttp://hdl.handle.net/10722/258364-
dc.description.abstractObjective: To compare S-1 with S-1 plus cisplatin (SP) as first-line treatment for metastatic gastric cancer. Methods: Records of patients with metastatic gastric cancer who received either the S-1 or SP regimen as first-line treatment for metastatic gastric cancer between January 2013 and December 2014 in Queen Mary Hospital were retrospectively reviewed. Baseline characteristics, overall response rate, median progression-free survival (PFS), overall survival (OS), and toxicity of the two groups were compared. Results: During the study period, 17 patients received S-1 and 13 patients received SP. The median patient ages were 69 and 57 years, respectively. In the S-1 group, more patients were aged ≥70 years (47.1% vs. 7.7%, p = 0.02), fewer patients underwent surgical resection of primary tumours (23.5% vs. 53.8%, p = 0.09), more patients required initial dose reduction (70.6% vs. 15.4%, p = 0.001), and fewer patients received subsequent chemotherapy (5.9% vs. 30.8%, p = 0.07) compared with the SP group. The S-1 group had a lower response rate (11.8% vs. 46.2%, p = 0.049). Nonetheless, S-1 and SP groups were comparable for clinical benefit rate (47.1% vs. 77.0%, p = 0.14), median PFS (34.5 weeks vs. 28.8 weeks, p = 0.72), median OS (46.4 weeks vs. 52.7 weeks, p = 0.18), and 30-day mortality (11.8% vs. 7.7%, p = 1.00). There was a trend of improved OS in the SP group (hazard ratio = 1.84, 95% confidence interval = 0.74-4.55, p = 0.185). The two groups were also comparable for the rate of grade 3/4 neutropaenia (17.7% vs. 38.5%, p = 0.24) and grade 3/4 diarrhoea (5.9% vs. 30.8%, p = 0.14). There was no treatment-related death. Conclusion: Both S-1 and SP regimens are effective and safe as first-line treatment for metastatic gastric cancer. A dose-adjusted S-1 regimen is a viable option for patients with advanced age and marginal performance status.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.org-
dc.relation.ispartofHong Kong Journal of Radiology-
dc.rightsHong Kong Journal of Radiology. Copyright © Hong Kong Academy of Medicine Press.-
dc.titleS-1 Versus S-1 Plus Cisplatin as First-line Treatment for Metastatic Gastric Cancer-
dc.typeArticle-
dc.identifier.emailLau, KS: lauks18@hku.hk-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.emailChan, WLW: winglok@hku.hk-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.emailKwong, DLW: dlwkwong@hku.hk-
dc.identifier.emailLeung, TW: ltw920@hkucc.hku.hk-
dc.identifier.authorityLam, KO=rp01501-
dc.identifier.authorityLee, VHF=rp00264-
dc.identifier.authorityKwong, DLW=rp00414-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.12809/hkjr1716810-
dc.identifier.hkuros286429-
dc.identifier.volume20-
dc.identifier.spage318-
dc.identifier.epage322-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats